Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC

被引:25
|
作者
Zhang, Chao [1 ,2 ]
Yan, Li-Xu [2 ,3 ]
Jiang, Ben-Yuan [1 ,2 ]
Wu, Yi-Long [1 ,2 ]
Zhong, Wen-Zhao [1 ,2 ]
机构
[1] Guangdong Prov Peoples Hosp, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou 510080, Guangdong, Peoples R China
[3] Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Peoples R China
关键词
D O I
10.1016/j.jtho.2019.12.133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:E95 / E99
页数:5
相关论文
共 50 条
  • [11] Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
    Ulhoi, Maiken Parm
    Sorensen, Boe Sandahl
    Meldgaard, Peter
    CASE REPORTS IN ONCOLOGY, 2021, 14 (03): : 1323 - 1327
  • [12] Ceritinib: a Review in ALK-Positive Advanced NSCLC
    Deeks, Emma D.
    TARGETED ONCOLOGY, 2016, 11 (05) : 693 - 700
  • [13] Ceritinib: a Review in ALK-Positive Advanced NSCLC
    Emma D. Deeks
    Targeted Oncology, 2016, 11 : 693 - 700
  • [14] Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC
    Hashimoto, Hiroshi
    Komori, Kazuyuki
    Kameda, Koji
    Taguchi, Shinichi
    Ozeki, Yuichi
    SURGICAL CASE REPORTS, 2022, 8 (01)
  • [15] Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib
    Cheung, Justin Matthew
    Kang, Jiyoon
    Yeap, Beow Y.
    Peterson, Jenn
    Do, Andrew
    Digumarthy, Subba R.
    Gainor, Justin F.
    Lin, Jessica Jiyeong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [16] Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib
    Cheung, Justin M.
    Kang, Jiyoon
    Yeap, Beow Y.
    Peterson, Jennifer L.
    Do, Andrew
    Gainor, Justin F.
    Digumarthy, Subba R.
    Lin, Jessica J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E31 - E31
  • [17] Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
    Lin, Jessica J.
    Jiang, Ginger Y.
    Joshipura, Nencyben
    Ackil, Jennifer
    Digumarthy, Subba R.
    Rincon, Sandra P.
    Yeap, Beow Y.
    Gainor, Justin F.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 683 - 690
  • [18] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients
    Yoshida, T.
    Oya, Y.
    Tanaka, K.
    Junichi, S.
    Yoshitsugu, H.
    Hida, T.
    Yatabe, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S619 - S619
  • [19] Efficacy and safety study with alectinib in advanced ALK-positive non-small-cell lung cancer
    Fernandez Madrigal, Laura
    Garcia Samblas, Victoria
    Amor Urbano, Maria
    Inoriza, Angel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [20] Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
    Kim, Dong-Wan
    Gadgeel, Shirish
    Gettinger, Scott N.
    Riely, Gregory J.
    Oxnard, Geoffrey R.
    Mekhail, Tarek
    Schmid, Peter
    Dowlati, Afshin
    Heist, Rebecca S.
    Wozniak, Antoinette J.
    Singh, Jatinder
    Cha, Edward
    Spahn, Jessica
    Ignatius, Sai-Hong
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (08):